key: cord-1048249-g9tsf7nb
authors: He, Ding-Dong; Zhang, Xiao-Kang; Zhu, Xin-Yu; Huang, Fang-Fang; Wang, Zi; Tu, Jian-Cheng
title: Network pharmacology and RNA-sequencing reveal the molecular mechanism of Xuebijing injection on COVID-19-induced cardiac dysfunction
date: 2021-02-22
journal: Comput Biol Med
DOI: 10.1016/j.compbiomed.2021.104293
sha: f25a6a203a6c0d49fafd265fc182736fc31aeaea
doc_id: 1048249
cord_uid: g9tsf7nb

BACKGROUND: Coronavirus disease 2019 (COVID-19) is an emerging infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Up to 20%–30% of patients hospitalized with COVID-19 have evidence of cardiac dysfunction. Xuebijing injection is a compound injection containing five traditional Chinese medicine ingredients, which can protect cells from SARS-CoV-2-induced cell death and improve cardiac function. However, the specific protective mechanism of Xuebijing injection on COVID-19-induced cardiac dysfunction remains unclear. METHODS: The therapeutic effect of Xuebijing injection on COVID-19 was validated by the TCM Anti COVID-19 (TCMATCOV) platform. RNA-sequencing (RNA-seq) data from GSE150392 was used to find differentially expressed genes (DEGs) from human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) infected with SARS-CoV-2. Data from GSE151879 was used to verify the expression of Angiotensin I Converting Enzyme 2 (ACE2) and central hub genes in both human embryonic-stem-cell-derived cardiomyocytes (hESC-CMs) and adult human CMs with SARS-CoV-2 infection. RESULTS: A total of 97 proteins were identified as the therapeutic targets of Xuebijing injection for COVID-19. There were 22 DEGs in SARS-CoV-2 infected hiPSC-CMs overlapped with the 97 therapeutic targets, which might be the therapeutic targets of Xuebijing injection on COVID-19-induced cardiac dysfunction. Based on the bioinformatics analysis, 7 genes (CCL2, CXCL8, FOS, IFNB1, IL-1A, IL-1B, SERPINE1) were identified as central hub genes and enriched in pathways including cytokines, inflammation, cell senescence and oxidative stress. ACE2, the receptor of SARS-CoV-2, and the 7 central hub genes were differentially expressed in at least two kinds of SARS-CoV-2 infected CMs. Besides, FOS and quercetin exhibited the tightest binding by molecular docking analysis. CONCLUSION: Our study indicated the underlying protective effect of Xuebijing injection on COVID-19, especially on COVID19-induced cardiac dysfunction, which provided the theoretical basis for exploring the potential protective mechanism of Xuebijing injection on COVID19-induced cardiac dysfunction.

In addition, patients with COVID-19 complicated with cardiac dysfunction have a significantly higher risk of poor prognosis [8] . A multi-center retrospective study showed that 13.7% of 657 COVID-19 patients had elevated creatine kinase (CK) levels, and 41% of patients were with increased lactate dehydrogenase (LDH). It's worth noting that the abnormally elevated CK and LDH were closely related to the poor prognosis of COVID-19 patients [9] . Han et al. showed that the higher concentration in venous blood of CK-MB, MYO, ultra TnI, and NT proBNP was associated with the severity and case fatality rate (CFR) of COVID 19 [10] . Shi et al. found that nearly 19 .7% of patients had myocardial injury among 416 hospitalized patients with severe COVID-19, and 51.2% of them eventually departed. In contrast, the mortality rate of patients without myocardial injury was only 4.5% [11] . This indicated that the occurrence of myocardial injury might increase the risk of death for COVID -19 patients by 3 to 4 times. A study involving 191 COVID-19 patients reported a higher proportion of heart failure patients in the death group compared with the cured group, suggesting that heart failure in patients infected with SARS-CoV-2 was a sign of poor prognosis [12] . A meta-analysis enrolled 43 studies containing 3,600 patients also came to a similar conclusion that the intensive group has a higher prevalence of heart failure compared with the non-intensive group [13] . These published studies manifest that in the treatment of severe and critically ill COVID-19 patients, in addition to the treatment of pneumonia, attention should also be paid to myocardial protection and the follow-up of myocardial markers. J o u r n a l P r e -p r o o f 7 

Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP, https://tcmspw.com/tcmsp.php) was used to identify the effective compounds of Xuebijing injection. Oral bioavailability (OB) ≥ 30 and drug-likeness (DL) ≥ 0.18 were set as the criteria for screening bioactive constituents of each component from Xuebijing injection [19] .

The compounds related target proteins were predicted depending on chemical similarities and pharmacophore models through TCMSP. Perl software was used to convert all protein names to gene names based on UniProt Knowledgebase (UniprotKB, https://www.uniprot.org/uniprot/).

The target genes that were commonly related with both COVID-19 and Xuebijing injection were obtained by taking the intersection of COVID-19 related therapeutic genes and the effective compounds related genes of Xuebijing injection. Cytoscape (3.7.2) software was used to construct the effective compounds-target genes network [20] .

RNA-seq data of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) infected with or without SARS-CoV-2 were obtained from GSE150392, J o u r n a l P r e -p r o o f which contained three controls and three cases [21] . For hiPSC-CMs with SARS-CoV-2 infection, viral inoculum (USA-WA1/2020, MOI=0.1) prepared using serum-free media was added. For hiPSC-CMs with mock infection, serum-free media alone was added. The inoculated plates were incubated for 1 hour at 37°C with 5% CO2. At the end of incubation, the inoculum was replaced with fresh hiPSC-CM culture medium. Cells remained at 37°C with 5% CO2 for 72 hours before analysis.

The R package named "limma" was adopted in the normalization of RNA-seq data and the identification of differentially expressed genes (DEGs) [22] . |log2(foldchange)| > 1 and adjusted p value < 0.05 were taken as the screening criteria.

GSEA was performed by WebGestalt (http://www.webgestalt.org) based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) and the Reactome Pathway Knowledgebase, respectively [23] [24] .

The R package "clusterProfiler" was utilized to implement Gene ontology (GO) enrichment analysis and KEGG pathway analysis [23, [25] [26] . More precisely, GO enrichment analysis was carried out within three classical subschemas: biological process (BP), cellular component (CC), and molecular function (MF). The cutoff value of statistical significance was set as p < 0.05.

J o u r n a l P r e -p r o o f Analysis of Protein-Protein Interaction (PPI) network is beneficial to explore the interactions of various proteins in complex diseases and it is helpful in systematically studying the molecular mechanism of diseases and distinguishing novel drug targets. In this study, STRING (v11.0) (https://string-db.org/) was utilized to establish a PPI network, 0.4 was set as the threshold of confidence score, and disconnected nodes in the network were hidden [27] . The PPI network was further visualized by Cytoscape 3.7.2. Subsequently, the central hub genes were screened based on the medians of six important topological parameters, including betweenness centrality (BC), closeness centrality (CC), degree centrality (DC), eigenvector centrality (EC), network centrality (NC), and local average connectivity (LAC).

GSE151879 contained RNA-seq data of hESC-derived cardiomyocytes (hESC-CMs) and adult human CMs with or without SARS-CoV-2 infection (USA-WA1/2020, MOI=0.1) [28] . Each subgroup included three samples. Cells were incubated at 37°C with 5% CO2 for 24 hours before analysis. GSE151879 was used to analyze the expression of ACE2 and central hub genes to validate the results of GSE150392.

The 2D structure of effective compounds was downloaded through PubChem (https://pubchem.ncbi.nlm.nih.gov/) and converted into 3D models by ChemOffice J o u r n a l P r e -p r o o f software. The X-ray crystal structures of the therapeutic target proteins were obtained from the RCSB PDB database (http://www.rcsb.org/). Molecular dockings of molecule ligands and protein receptors were performed by AutoDock Vina, and the binding free energy was utilized as the basis for evaluating the docking results.

The research flow diagram of this study was shown in Figure 1 . It can be noticed from the results exhibited in Table 1 that the therapeutic effect of Xuebijing injection on COVID-19 was almost equal to the positive control (HSBD), indicating the therapeutic ability of Xuebijing injection was quite compelling. The curative potential of the 5 traditional Chinese medicine herbs in Xuebijing injection was also evaluated through TCMATCOV. Hong Hua, Chuan Xiong and Dang Gui were all identified with satisfactory therapeutic effects on COVID-19, while Dan Shen showed rather mediocre curative ability. Chi Shao was not enrolled in the analysis due to the deficiency of corresponding pharmacological data in TCMATCOV.

COVID-19 related therapeutic target genes were retrieved in five databases, including 11 from DrugBank, 698 from GeneCard, 419 from OMIM, 90 from TTD, and 114 from TCMATCOV ( Figure 2A , Table S1 ). After removing duplicate targets, a total of 1279 COVID-19 related therapeutic targets were confirmed. J o u r n a l P r e -p r o o f

A total of 459 effective compounds and 495 target proteins from five traditional Chinese herbs in Xuebijing injection were distinguished through the TCMSP database (Table S2 ). Among them, 97 proteins were identified as the therapeutic targets of Xuebijing injection for COVID-19 ( Figure 2B ).

The effective compound-target network of Xuebijing injection on COVID-19 was constructed to elaborate the multiplex interplay that contained 323 nodes (226 effective compounds and 97 target proteins) and 630 edges ( Figure 2C ). The 2 peripheral rings were composed of 97 target proteins. The deeper color and the larger radius represented the greater connectivity among target proteins and effective compounds. In the inner layer, the yellow circle represented effective ingredients in Chi Shao, the orange circle represented effective ingredients in Chuan Xiong, the green circle represented effective ingredients in Dang Gui, the blue circle represented effective ingredients in Hong Hua, the pink circle represented effective ingredients in Dan Shen, and the effective ingredients that commonly existed in multiple herbs were exhibited by the purple circle.

To further explore the underlying curative targets of Xuebijing injection on COVID-19-induced cardiac insufficiency, GSE150392 was enrolled in analysis and 

The GO functional enrichment analysis revealed that the 22 hub DEGs were enriched in multiple BP related terms, including response to lipopolysaccharide, regulation of apoptotic signaling pathway, cellular response to lipopolysaccharide, and positive regulation of cytokine biosynthetic process ( Figure 6A ). The hub DEGs were also observed to be enriched in Wnt signalosome and beta-catenin destruction complex, which belonged to the CC group. Cytokine related MF terms were enriched by the majority of the hub DEGs, such as cytokine activity, cytokine receptor binding, receptor ligand activity, chemokine activity, chemokine receptor binding and interleukin-1 receptor binding.

The results of KEGG pathway analysis revealed that the 22 hub DEGs mainly participated in pathways associated with inflammatory injury and cardiac dysfunction, including IL-17 signaling pathway, TNF signaling pathway, fluid shear stress and atherosclerosis, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, MAPK J o u r n a l P r e -p r o o f Signaling pathway, cellular senescence, necroptosis and so on. In addition, the pathological mechanism of COVID-19-induced cardiac dysfunction might be similar to that in Pertussis and Influenza A ( Figure 6B ).

After hiding disconnected nodes, the 22 hub DEGs formed a PPI network with 19 nodes and 63 edges ( Figure 7A ). The up-regulated genes in SARS-CoV-2 infected hiPSC-CMs were shown in red, while the down-regulated ones were shown in blue.

The deeper color of the genes indicated increased log2 (foldchange), and the larger diameter stood for a more significant statistical difference. According to the screening Figure 7C ).

To enhance the reliability of our research, we added another dataset (GSE151879) to validate the expression status of ACE2 and 7 central hub genes. Combining the data from GSE150392 and GSE151879, we found ACE2 and 7 central hub genes were all differentially expressed in at least two kinds of SARS-CoV-2 infected CMs (hiPSC-CMs, hESC-CMs, adult human CMs) ( Figure 8 , Table S3 ). Besides, ACE2 was down-regulated and 7 hub genes were up-regulated.

The 7 central hub genes and their corresponding effective compounds from the components of Xuebijing injection were displayed in Figure 9A . In order to further verify the binding ability of the effective compounds with hub targets, molecular docking was performed. The results of molecular docking were shown in Table 2, where FOS and quercetin exhibited the tightest binding ( Figure 9B ).

COVID-19 has developed into a global pandemic, which is caused by SARS-CoV-2. COVID-19 mainly manifests as respiratory symptoms, but cardiac complications such as arrhythmia, heart failure, and viral myocarditis are also prevalent [29] [30] . Xuebijing injection has been adopted in the adjuvant treatment of severe and critical COVID-19 patients, and has been proved to have a protective effect on myocardial injury induced by infection and inflammation [15] [16] [17] . Therefore, we speculated that Xuebijing injection might also have a therapeutic effect on COVID-19-induced cardiac dysfunction. Meanwhile, the increased SERPINE1 could cause endothelial cell injury [32] . Another study stated that the CCL2+ inflammatory macrophage amount was abundant in peripheral blood of severe COVID-19 patients and inflammatory genes such as IL-1B were highly expressed in the CCL2+ inflammatory macrophages [33] . CXCL8, IL-1B, FOS and IFNB1 were identified to be up-regulated in COVID-19 patients and it was suggested that IFN-β might play a pivotal role in exacerbating inflammation in severe COVID-19 patients by enhancing TNF/IL-1B-driven inflammation [34] . Moreover, J o u r n a l P r e -p r o o f increased IFNB1 could upregulate the SARS-CoV-2 receptor ACE2, which promoted the course of disease in patients with COVID-19 [35] .

The published investigations suggested the mechanisms of myocardial injury secondary to COVID-19 infection mainly included direct damage to the CMs, systemic inflammation, myocardial interstitial fibrosis, interferon mediated immune response and hypoxia [36] . Previous studies have confirmed the biological role of the 7 central hub genes in cardiac dysfunction. For example, the increased inflammatory cytokines and chemokines such as IL-1A, IL-1B and CCL2 led to oxidative stress, endothelial dysfunction and hypercoagulation, thus increasing the risk of cardiovascular events [37] [38] . As a nonselective IL-1 antagonist acting on both IL-1A and IL-1B receptors, anakinra has been verified to be beneficial for treating severe COVID-19 patients [39] .

Considering anakinra is also effective in improving cardiac function [40] , it could be assumed that COVID-19-induced cardiac dysfunction might be improved by restraining the function of IL1-A and IL-1B. In addition, Frangogiannis et al. revealed that CCL2 and CXCL8 were markedly increased in the infarcted myocardium and might regulate leukocyte infiltration and granulation tissue formation [41] . Besides, the upregulation of CXCL8 in CMs could lead to damage of actomyosin cytoskeleton distribution and mitochondrial network organization [42] . AP-1 (c-JUN/c-FOS) was also reported to be involved in cardiac remodeling, myocardial dysfunction and progression of heart failure [43] .

From the results of the molecular docking simulation, 6 out of the 7 central hub J o u r n a l P r e -p r o o f genes (CCL2, CXCL8, FOS, IL-1A, IL-1B, SERPINE1) could be molecularly docked with quercetin, hinting the crucial role of quercetin in the pharmacology network. It has been reported that quercetin could inhibit angiotensin-induced cardiac fibrosis [44] .

In addition, quercetin was found to against myocardial ischemia reperfusion injury through alleviating oxidative stress injury, exerting anti-inflammatory and anti-apoptotic effects [45] . Apigenin was the molecular ligand that could be bound by both FOS and SERPINE1. Apigenin could attenuate the differentiation of cardiac fibroblasts, reduce the mitochondrial/lysosome damage and oxidative stress of CMs [46] [47] . The common ligand shared by CXCL8 and IL-1B was rutin, which was demonstrated to improve myocardial damage via miR-22-5p-regulated RAP1/ERK signaling pathway [48] . FOS and IL-1B might attenuate the mitochondrial and lysosomal dysfunction through docking with ursolic acid [49] . Combining the published studies and our bioinformatics analysis, we hypothesized that Xuebijing injection might play a protective effect on COVID-19-induced cardiac dysfunction by targeting the 7 central hub genes.

Finally, a pathway diagram of the underlying mechanism of the 7 central hub genes in CMs infected with SARS-CoV-2 was established ( Figure 10 ). Our bioinformatics analysis found ACE2 was significantly down-regulated in SARS-CoV-2 infected CMs, which was consistent with the prior reports of examining SARS-CoV-2 infected myocardium [50] . SARS-CoV-2 mediated myocardial apoptosis, cardiogenic shock, myocardial ischemia and inflammatory injury were related to the J o u r n a l P r e -p r o o f down-regulation of ACE2 in the myocardium [51] [52] . The spike protein of SARS-CoV-2 might bind to TLR4 to trigger transmembrane stimulation [53] [54] . Then, TLR4 activated interferon (IFN)-regulatory factors (IRF3 and IRF7), leading to increased expression of one of the hub genes IFNB1 and further enhancive the secretion of IFN-β [55] [56] . It has been proved the increased IFN-β could stimulate STAT1 and finally resulting in myocardial fibrosis [57] [58] . Besides, the TLR4-induced c-JUN/c-FOS activation could enhance the expression of ACE2, so that more SARS-CoV-2 could entry into the host cells via ACE2 as a receptor [59] [60] . At the same time, the activited c-JUN/c-FOS eventually accelerated the apoptosis of CMs [61] . Herman et al. and Lavrentyev et al. demonstrated the hub gene CCL2 bound to its receptor CCR2 and activated the protein kinase C (PKC) signaling pathway, inducing the increase of AP-1 (c-JUN/c-FOS), NF-κB and ACE2, and ultimately leading to CM apoptosis and myocardial ischemia [62] [63] . Likewise, the NF-κB signaling pathway could also be activated by IL-1A and IL-1B, two hub genes of our analysis, and subsequently contributed to myocardial ischemia [64] [65] . The combination of CXCL8 and its receptor CXCR1/2 promoted cell senescence, and enhanced cell invasion in conjunction with another hub gene SERPINE1 through matrix metalloprotein (MMP) pathway [66] [67] . Hence Xuebijing injection might play a protective role on COVID-19-induced cardiac dysfunction by inhibiting the above pathways correlated with the 7 central hub genes.

Although we conducted a series of analysis to illustrate the potential protective J o u r n a l P r e -p r o o f mechanism of Xuebijing injection on COVID-19-induced cardiac dysfunction, there were still some limitations in this research: (1) The expression levels of the 7 central hub genes were verified in two published datasets and showed a high degree of consistency in three kinds of CMs (hiPSC-CMs, hESC-CMs, adult human CMs) infected with SARS-CoV-2, but the total sample size was still limited. (2) The two datasets (the type and MOI of virus added in the two models were the same while the processing time was different) contained RNA-seq data of only one single time point after SARS-CoV-2 infection, which also marked the limitation of the current study. (3) Since the development of COVID-19 involves complex pathological processes, the mechanism predicted above of Xuebijing injection in treating COVID-19-induced cardiac dysfunction still needs to be further verified by in vivo and in vitro experiments.

(4) Though the effectiveness and safety of Xuebijing injection have been clinically demonstrated in large numbers of Chinese COVID-19 patients [68] [69] , the efficacy and security of Xuebijing injection in treating patients of other ethnicities still require careful evaluation.

In conclusion, our bioinformatics analysis indicated the underlying protective effect of Xuebijing injection on COVID-19, especially on COVID19-induced cardiac dysfunction. Xuebijing injection might treat COVID-19-induced cardiac dysfunction through inhibiting oxidative stress, preventing atherosclerotic plaque formation, J o u r n a l P r e -p r o o f restraining inflammatory and apoptosis by targeting 7 hub genes (CCL2, CXCL8, FOS, IFNB1, IL-1A, IL-1B, SERPINE1). Our research provided a theoretical basis for exploring the potential protective mechanism of Xuebijing injection on COVID-19-induced cardiac dysfunction.

DDH and XKZ designed the project, drafted the manuscript and visualized the data.

XYZ, FFH, ZW were involved in data analysis and interpretation. JCT revised the manuscript. All authors approved the final manuscript. 

The authors declare that this study received funding from Ningbo MedicalSystem Biotechnology Co., Ltd. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Not applicable.

Not applicable.

Infection., Cell Reports. Med. 1 (2020) 100052. The GESA enrichment plots of typical pathways. While the borders of DEGs with p value > 0.05 were marked in gray. 

A Novel Coronavirus from Patients with Pneumonia in China

Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

SARS-CoV-2: a potential novel etiology of fulminant myocarditis

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

ST-Segment Elevation in Patients with Covid-19 -A Case Series

Myocardial injury and COVID-19: Serum hs-cTnI level in risk stratification and the prediction of 30-day fatality in COVID-19 patients with no prior cardiovascular disease

Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients

Clinical Characteristics of Coronavirus Disease 2019 in China

Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis

XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia: A Randomized Controlled Trial

The study on the treatment of Xuebijing 706-710

Effects of xuebijing injection on cardiac function and structure in rats with myocardial hypoxia/reoxygenation injury]., Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese

TCMSP: a database of systems pharmacology for drug discovery from herbal medicines

Cytoscape: a software environment for integrated models of biomolecular interaction networks

Human iPSC-Derived Cardiomyocytes Are Susceptible to

limma powers differential expression analyses for RNA-sequencing and microarray studies

KEGG: new perspectives on genomes, pathways, diseases and drugs

The reactome pathway knowledgebase

He, clusterProfiler: an R package for comparing biological themes among gene clusters

STRING v9.1: protein-protein interaction networks, with increased coverage and integration

SARS-CoV-2 Infected Cardiomyocytes Recruit Monocytes by Secreting CCL2

The Variety of Cardiovascular Presentations of COVID-19

Potential Effects of Coronaviruses on the Cardiovascular System: A Review

Platelets Promote Thromboinflammation in SARS-CoV-2 Pneumonia

trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome

IFN-γ and TNF-α drive a CXCL10 + CCL2 + macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation

Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19

Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon

Myocardial injury and COVID-19: Possible mechanisms

Obesity and COVID-19: immune and metabolic derangement as a possible link to adverse clinical outcomes

Dexamethasone, pro-resolving lipid mediators and resolution of inflammation in COVID-19

Giamarellos-Bourboulis, Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis

Differential effects of inhibition of interleukin 1 and 6 on myocardial

Chemokines in myocardial ischemia

Inflammatory cytokines associated with cancer growth induce mitochondria and cytoskeleton alterations in cardiomyocytes

miR-146a targets Fos expression in human cardiac cells

Quercetin Dihydrate inhibition of cardiac fibrosis induced by angiotensin II in vivo and in vitro

Protective Mechanisms of Quercetin Against Myocardial Ischemia Reperfusion Injury

Apigenin attenuates TGF-β1-stimulated cardiac fibroblast differentiation and extracellular matrix production by targeting miR-155-5p/c-Ski/Smad pathway

Apigenin attenuates Aluminum phosphide-induced cytotoxicity via reducing mitochondrial/Lysosomal damages and oxidative stress in rat Cardiomyocytes

Rutin treats myocardial damage caused by pirarubicin via regulating miR-22-5p-regulated RAP1/ERK signaling pathway

Ursolic acid modulates MMPs, collagen-I, α-SMA, and TGF-β expression in isoproterenol-induced myocardial infarction in rats

Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Platform to Study SARS-CoV-2 Related Myocardial Injury

The diagnostic value of circulating microRNAs in heart failure

COVID 19 gate way to multiple organ failure syndromes

Is Toll-like receptor 4 involved in the severity of COVID-19 pathology in patients with cardiometabolic comorbidities?

COVID-19 Patients Upregulate Toll-like Receptor 4-mediated Inflammatory Signaling That Mimics Bacterial Sepsis

Toll-like receptor signalling

Role of Toll-like receptors and interferon regulatory factors in different experimental heart failure models of diverse etiology: IRF7 as novel cardiovascular stress-inducible factor

The Role of IFN-β during the Course of Sepsis Progression and Its Therapeutic Potential

synergistically regulate cardiac fibrosis induced by high glucose

Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Activator protein-1 and caspase 8 mediate p38α MAPK-dependent cardiomyocyte apoptosis induced by palmitic acid

Curcumin blocks CCL2-induced adhesion, motility and invasion, in part, through down-regulation of CCL2 expression and proteolytic activity

High glucose-induced Nox1-derived superoxides downregulate PKC-betaII, which subsequently decreases ACE2 expression and ANG(1-7) formation in rat VSMCs

TORn about SASP regulation

The role of IL-1B in breast cancer bone metastasis

The Chemokine CXCL8 in Carcinogenesis and Drug Response

PAI-1 in tissue fibrosis

Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China

Combating COVID-19 with integrated traditional Chinese and Western medicine in China